Following takeover target Shire’s (LSE: SHP) waiver of the three-day notice period, AbbVie (NYSE: ABBV) said this morning that its board of directors has withdrawn its recommendation made on July 18, to acquire the Ireland-based drugmaker and recommends that stockholders vote against the transaction,
This news comes hot on the heels of AbbVie’s announcement yesterday that it planned a board meeting on Monday to reconsider its tax-inversion motivated $54.6 billion bid for Shire in the wake of US Treasury Department changes to tax regulations.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze